Literature DB >> 19690868

Considerations for the management of urgency symptoms in patients with overactive bladder syndrome.

Linda D Cardozo1, Philip E V A Van Kerrebroeck, David R Staskin.   

Abstract

INTRODUCTION: Traditionally, urinary frequency and/or urgency incontinence have been the primary outcome measurements for the symptom complex of overactive bladder (OAB). However, urgency, by definition, precedes urgency incontinence, and drives frequency and nocturia in OAB and should be considered in this pivotal role.
MATERIALS AND METHODS: Review of published literature on this topic.
RESULTS: The management of urgency is evolving as of major clinical importance to patients. Recent use of diary-based urgency metrics has advanced our knowledge of the presence and nature of urgency symptoms, the impact on QoL and the response to treatment options.
CONCLUSION: It is logical that the management of the number of urgency episodes and the degree of urgency, as well as the impact and bother associated with this core symptom are all taken into consideration along with patient interpretation to facilitate an effective outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690868     DOI: 10.1007/s00345-009-0455-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  53 in total

1.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

Review 2.  The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.

Authors:  Christopher Chapple; Vik Khullar; Zahava Gabriel; Julie Ann Dooley
Journal:  Eur Urol       Date:  2005-03-22       Impact factor: 20.096

Review 3.  Lower urinary tract symptomatology: Its definition and confusion.

Authors:  Yukio Homma
Journal:  Int J Urol       Date:  2008-01       Impact factor: 3.369

Review 4.  Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults.

Authors:  A A Alhasso; J McKinlay; K Patrick; L Stewart
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.

Authors:  C R Chapple; R Martinez-Garcia; L Selvaggi; P Toozs-Hobson; W Warnack; T Drogendijk; D M Wright; J Bolodeoku
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

Review 6.  Botulinum toxin for the management of bladder dysfunction.

Authors:  Brigitte Schurch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.

Authors:  Kathryn L Burgio; Stephen R Kraus; Shawn Menefee; Diane Borello-France; Marlene Corton; Harry W Johnson; Veronica Mallett; Peggy Norton; Mary P FitzGerald; Kimberly J Dandreo; Holly E Richter; Thomas Rozanski; Michael Albo; Halina M Zyczynski; Gary E Lemack; Toby C Chai; Salil Khandwala; Jan Baker; Linda Brubaker; Anne M Stoddard; Patricia S Goode; Betsy Nielsen-Omeis; Charles W Nager; Kimberly Kenton; Sharon L Tennstedt; John W Kusek; T Debuene Chang; Leroy M Nyberg; William Steers
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

8.  Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.

Authors:  Norman Zinner; Les Noe; Lawrence Rasouliyan; Thomas Marshall; Raafat Seifeldin
Journal:  Curr Med Res Opin       Date:  2008-04-17       Impact factor: 2.580

Review 9.  Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.

Authors:  F Haab; L Stewart; P Dwyer
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

10.  Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.

Authors:  David Staskin; Peter Sand; Norman Zinner; Roger Dmochowski
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.